Effects of Rifampin on the Disposition of Gepirone ER and Its Metabolites
Authors:
- Y.W Francis LamYLY.W Francis Lam
- Larry EreshefskyLELarry Ereshefsky
- Andreas PortAPAndreas Port
- Cees J TimmerCTCees J Timmer
- Peter DogteromPDPeter Dogterom
Open Access
- 16 January 2009
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Drug Metabolism Journal
- Vol. 3 (1) , 1-7
Abstract
Effects of Rifampin on the Disposition of Gepirone ER and Its MetabolitesKeywords
This publication has 11 references indexed in Scilit:
- Effect of rifampicin on the pharmacokinetics of pioglitazoneBritish Journal of Clinical Pharmacology, 2005
- Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazoneClinical Pharmacology & Therapeutics, 2004
- Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizideClinical Pharmacology & Therapeutics, 2001
- Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepirideBritish Journal of Clinical Pharmacology, 2000
- Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrationsClinical Pharmacology & Therapeutics, 2000
- Concentrations and effects of buspirone are considerably reduced by rifampicinBritish Journal of Clinical Pharmacology, 1998
- Triazolam is ineffective in patients taking rifampinClinical Pharmacology & Therapeutics, 1997
- Noninvasive tests of CYP3A enzymesPharmacogenetics, 1994
- Updated clinical safety experience with fluvastatinThe American Journal of Cardiology, 1994
- Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.British Journal of Clinical Pharmacology, 1986